EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: Merck KGaA, Darmstadt, Germany
Terminated
Study terminated due to potential safety concerns in combination with platinum-based therapies
Other terminated trials from Merck KGaA, Darmstadt, Germany
Other Squamous Cell Carcinoma of the Head and Neck trials with similar outcome
Browse all Squamous Cell Carcinoma of the Head and Neck trials
This PHASE1 trial investigates Squamous Cell Carcinoma of the Head and Neck and is currently terminated or withdrawn. Merck KGaA, Darmstadt, Germany leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .